| 178.75 -3.53 (-1.94%) | 06-12 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term | |
|||
| Targets | 6-month : | 216.13 | 1-year : | 223.67 |
| Resists | First : | 185.04 | Second : | 191.5 |
| Pivot price | 182.46 |
|||
| Supports | First : | 174.6 | Second : | 145.26 |
| MAs | MA(5) : | 180.99 |
MA(20) : | 183.21 |
| MA(100) : | 191.3  |
MA(250) : | 173.65 |
|
| MACD | MACD : | -2.1 |
Signal : | -2.1 |
| %K %D | K(14,3) : | 33.3 |
D(3) : | 38 |
| RSI | RSI(14): 42.8 |
|||
| 52-week | High : | 210.51 | Low : | 134.86 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ AZN ] has closed above bottom band by 23.4%. Bollinger Bands are 27.9% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 183.13 - 184.03 | 184.03 - 184.76 |
| Low: | 176.09 - 177.32 | 177.32 - 178.32 |
| Close: | 177.05 - 178.89 | 178.89 - 180.38 |
AstraZeneca PLC operates as a global biopharmaceutical leader, dedicated to the entire process of bringing prescription medicines to market, from their initial discovery and development through manufacturing and commercialization. The company's extensive portfolio of treatments, including prominent examples like Tagrisso, Farxiga, and Symbicort, addresses critical areas such as cardiovascular, renal, metabolic, and oncological conditions. Furthermore, it provides essential solutions for COVID-19 and various rare diseases, with products like Vaxzevria and Soliris. AstraZeneca engages with primary and specialty care physicians worldwide, facilitating distribution through a robust network of representatives and local offices across the United Kingdom, continental Europe, the Americas, Asia, Africa, and Australasia. The firm actively drives innovation through strategic collaborations, partnering with entities such as Neurimmune AG for the development and commercialization of NI006, BenevolentAI for systemic lupus erythematosus drug discovery, Lunit for AI-powered digital pathology risk assessment in NSCLC, and Absci Corporation for AI-driven oncology target identification. Founded in 1992, the company was initially known as Zeneca Group PLC, subsequently rebranding to AstraZeneca PLC in April 1999, and maintains its headquarters in Cambridge, United Kingdom.
Mon, 15 Jun 2026
US approves AstraZeneca (NYSE: AZN) Truqap combo for PTEN-deficient metastatic prostate cancer - Stock Titan
Mon, 15 Jun 2026
FDA Grants Priority Review to AstraZeneca’s Ultomiris for Rare Kidney Disease Treatment (AZN) - Yahoo Finance UK
Mon, 15 Jun 2026
Astrazeneca Plc Gains US Approval For Truqap In PTEN-deficient Prostate Cancer - DirectorsTalk Interviews
Sat, 13 Jun 2026
CVT Nasdaq-100 Index Portfolio's AstraZeneca PLC(AZN) Holding History - GuruFocus
Fri, 12 Jun 2026
AstraZeneca (AZN) Secures U.S. Approval for Innovative Prostate Cancer Treatment - GuruFocus
Fri, 12 Jun 2026
AstraZeneca Truqap Ok'd in U.S. for prostate cancer (AZN:NYSE) - Seeking Alpha
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Outperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NYSE
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Drug Manufacturers - General
|
|
| Shares Out | 1,550 (M) |
| Shares Float | 1,540 (M) |
| Held by Insiders | 0 (%) |
| Held by Institutions | 65 (%) |
| Shares Short | 2,160 (K) |
| Shares Short P.Month | 1,740 (K) |
| EPS | 6.65 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 30.55 |
| Profit Margin | 17.1 % |
| Operating Margin | 27.9 % |
| Return on Assets (ttm) | 8.4 % |
| Return on Equity (ttm) | 23.4 % |
| Qtrly Rev. Growth | 12.5 % |
| Gross Profit (p.s.) | 31.78 |
| Sales Per Share | 38.99 |
| EBITDA (p.s.) | 12.92 |
| Qtrly Earnings Growth | 5.3 % |
| Operating Cash Flow | 14,220 (M) |
| Levered Free Cash Flow | 6,560 (M) |
| PE Ratio | 26.87 |
| PEG Ratio | 1.4 |
| Price to Book value | 5.84 |
| Price to Sales | 4.58 |
| Price to Cash Flow | 19.48 |
| Dividend | 2.15 |
| Forward Dividend | 0 |
| Dividend Yield | 1.2% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|